What is Leerink Partnrs’ Estimate for argenx Q1 Earnings?

argenx SE (NASDAQ:ARGX) – Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of argenx in a note issued to investors on Friday, February 28th. Leerink Partnrs analyst T. Smith expects that the company will earn $2.04 per share for the quarter. The consensus estimate for argenx’s current full-year earnings is $3.13 per share. Leerink Partnrs also issued estimates for argenx’s Q2 2025 earnings at $2.40 EPS, Q3 2025 earnings at $2.71 EPS and Q4 2025 earnings at $3.02 EPS.

Several other equities research analysts have also weighed in on the company. Wolfe Research raised argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price objective for the company in a research note on Tuesday, November 12th. Wedbush reissued an “outperform” rating and issued a $655.00 price target on shares of argenx in a research note on Tuesday, December 3rd. Robert W. Baird boosted their target price on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research note on Tuesday. William Blair reiterated an “outperform” rating on shares of argenx in a report on Friday, February 28th. Finally, Oppenheimer increased their price objective on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $662.83.

argenx Price Performance

NASDAQ ARGX opened at $621.25 on Monday. The company has a market capitalization of $37.75 billion, a P/E ratio of -705.97 and a beta of 0.58. argenx has a 12 month low of $349.86 and a 12 month high of $678.21. The company’s 50 day simple moving average is $642.51 and its 200 day simple moving average is $591.91.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $761.22 million for the quarter, compared to analysts’ expectations of $678.52 million.

Institutional Trading of argenx

Institutional investors and hedge funds have recently modified their holdings of the company. US Bancorp DE increased its stake in argenx by 7.8% in the third quarter. US Bancorp DE now owns 4,350 shares of the company’s stock valued at $2,358,000 after acquiring an additional 316 shares during the period. Janney Montgomery Scott LLC boosted its holdings in shares of argenx by 201.2% in the 3rd quarter. Janney Montgomery Scott LLC now owns 2,072 shares of the company’s stock worth $1,123,000 after acquiring an additional 1,384 shares in the last quarter. Nvwm LLC acquired a new stake in argenx during the 3rd quarter valued at $533,000. Keudell Morrison Wealth Management acquired a new position in argenx during the 3rd quarter worth about $207,000. Finally, Assetmark Inc. increased its holdings in shares of argenx by 8.3% in the third quarter. Assetmark Inc. now owns 7,769 shares of the company’s stock valued at $4,211,000 after purchasing an additional 598 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.